Latest news with #JorgeReis-Filho
Business Wire
2 days ago
- Business
- Business Wire
Modella AI Announces Agreement to Accelerate AI-Driven Oncology Clinical Development
BOSTON--(BUSINESS WIRE)-- Modella AI, a leader in artificial intelligence for life sciences, today announced a multi-year agreement with AstraZeneca. Under the agreement, Modella AI will provide access to its state-of-the-art multi-modal AI foundation models to AstraZeneca. This agreement aims to harness Modella AI's advanced foundation models, capable of rich feature extraction from diverse data types, to accelerate clinical development across AstraZeneca's global oncology portfolio. 'Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents,' said Jill Stefanelli, CEO of Modella AI. 'Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca's research engine, they will have the potential to accelerate data driven development and enable the development of new AI agents that can automate complex R&D workflows.' AstraZeneca will leverage Modella AI's platform to enhance its oncology R&D capabilities, with the goal of enhancing clinical development, biomarker discovery, and improving patient outcomes. Both companies will collaborate closely to integrate the models into AstraZeneca's research pipeline, enabling data-driven discovery at increased scale and speed. 'At AstraZeneca, AI is integrated across every aspect of clinical development,' said Jorge Reis-Filho, Chief AI and Data Scientist, Oncology R&D, AstraZeneca. 'Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.' About Modella AI Modella AI ( is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. By combining expertise in artificial intelligence and pathology, Modella AI aims to deliver innovative solutions that empower clinicians, improve patient outcomes, and transform medical workflows. Disclaimer: This release may contain forward-looking statements based on current assumptions and forecasts made by Modella AI management. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Yahoo
25-04-2025
- Business
- Yahoo
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the foundation model will be used to extract biological and clinical insights, identify novel drug targets, and support the development of new cancer therapies. Under the terms of the deal, Tempus will receive $200m in data licencing and model development fees. The company will contribute its large library of de-identified oncology data to help build the model, which will be shared by all three parties once completed. Tempus' shares, listed on the Nasdaq exchange, rose 14.6% on 23 April following the announcement, closing at $49.55, up from $43.23 the previous day. 'Generative artificial intelligence (AI) and the emergence of large multimodal models is the final catalyst needed to usher in precision medicine in oncology at scale,' said Tempus' CEO Eric Lefkofsky. 'Tempus has spent the last decade investing billions of dollars into collecting the necessary data needed for a foundation model of this kind to take shape.' The partnership builds on an existing relationship between Tempus and AstraZeneca. The two companies first teamed up in 2021, announcing an AI-driven oncology R&D alliance. In 2023, they expanded the partnership with the deployment of Tempus' Next platform to support clinical decision-making for non-small cell lung cancer (NSCLC) patients, helping physicians determine whether patients should undergo guideline-directed molecular testing. AstraZeneca is also advancing its use of AI across multiple areas of drug development. "Cancer drug discovery and clinical development are being transformed by the ability to analyse vast amounts of rich data using artificial intelligence," said Jorge Reis-Filho, chief AI and data scientist of oncology R&D at AstraZeneca. The company has pursued other AI collaborations as well, including a deal with biological simulation company Turbine. Announced in January 2024, the partnership uses AI-driven simulations to explore drug resistance mechanisms in blood cancers, aiming to predict drug interactions and identify potential combination therapies. Unlike traditional lab-based methods, these models can generate millions of simulations to analyse complex biological pathways at a fraction of the time. AstraZeneca's senior director in oncology data science Krishna Bulusu recently shared that AI is transforming drug discovery, but its implementation must be thoughtful and strategic. He said at the ELRIG Drug Discovery meeting in London on 11 March 2025 that AI must be a 'thought partner' in drug discovery. The use of AI in drug development continues to gain momentum across the pharma industry. According to a survey by GlobalData, the parent company of Pharmaceutical Technology, AI is considered the most disruptive technology among businesses, including in the healthcare industry. Earlier in April 2025, Eli Lilly entered a research partnership with BigHat Biosciences to co-develop antibody therapeutics using BigHat's AI-based Milliner platform. BigHat has also signed agreements with Johnson & Johnson (J&J), AbbVie, MSD, and Amgen. "AstraZeneca enters $200m AI cancer pact with Tempus and Pathos" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Wire
23-04-2025
- Business
- Business Wire
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community. Tempus' de-identified oncology data will be used to build the foundation model. Upon completion, the model will be shared among all three parties to advance their individual efforts to improve patient care. The agreements include $200 million in data licensing and model development fees to Tempus. The agreement with AstraZeneca expands on the strategic partnership between the two companies announced in 2021 and aims to leverage Tempus' AI-enabled platform and vast repository of multimodal data to advance novel therapeutic programs in oncology on a global scale. 'Generative AI and the emergence of large multimodal models is the final catalyst needed to usher in precision medicine in oncology at scale,' said Eric Lefkofsky, Founder and CEO of Tempus. 'Tempus has spent the last decade investing billions of dollars into collecting the necessary data needed for a foundation model of this kind to take shape. We look forward to working with AstraZeneca and Pathos to apply AI-enabled solutions to advance therapies in an effort to help patients live longer and healthier lives.' 'Cancer drug discovery and clinical development are being transformed by the ability to analyze vast amounts of rich data using artificial intelligence,' said Jorge Reis-Filho, Chief AI and Data Scientist, Oncology R&D, AstraZeneca. 'We are excited to collaborate with Tempus and Pathos to advance our data and AI-driven R&D strategy through the development of a multimodal oncology foundation model that we believe will accelerate and increase the probability of clinical success across our diverse pipeline.' "As artificial intelligence becomes more prominent in drug discovery and development, the opportunity for companies like Pathos to build foundation models that seemed almost unimaginable a few years ago is now taking shape,' said Mohamad Makhzoumi, Co-CEO of NEA and Pathos Board Member. 'We couldn't be more excited to collaborate with Tempus and AstraZeneca given the potential of these models to improve patient outcomes." About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of the largest multimodal foundation model in oncology therapeutic research and discovery, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
